Vor Biopharma Target of Unusually High Options Trading (NASDAQ:VOR)

Vor Biopharma Inc. (NASDAQ:VOR) was the recipient of unusually large options trading activity on Tuesday. Stock traders purchased 8,702 put options on the stock. This represents an increase of approximately 87% compared to the typical volume of 4,658 put options.

Analyst Upgrades and Downgrades

A number of analysts recently commented on VOR shares. Stifel Nicolaus upgraded shares of Vor Biopharma from a “hold” rating to a “buy” rating and set a $55.00 price target on the stock in a research note on Wednesday, September 24th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Vor Biopharma in a report on Wednesday, October 8th. Zacks Research lowered Vor Biopharma from a “hold” rating to a “strong sell” rating in a research note on Monday, October 13th. Baird R W raised Vor Biopharma from a “hold” rating to a “strong-buy” rating in a report on Wednesday, October 15th. Finally, HC Wainwright boosted their price objective on Vor Biopharma to $52.00 and gave the stock a “buy” rating in a report on Wednesday, October 29th. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, three have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $76.50.

Insiders Place Their Bets

In other news, Director Ra Capital Management, L.P. sold 24,579 shares of Vor Biopharma stock in a transaction dated Thursday, October 30th. The shares were sold at an average price of $25.12, for a total transaction of $617,424.48. Following the completion of the transaction, the director directly owned 779,652 shares in the company, valued at $19,584,858.24. This trade represents a 3.06% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, major shareholder Reprogrammed Interchange Llc sold 11,616 shares of the business’s stock in a transaction dated Monday, October 20th. The stock was sold at an average price of $30.05, for a total transaction of $349,060.80. Following the sale, the insider directly owned 1,167,109 shares of the company’s stock, valued at approximately $35,071,625.45. The trade was a 0.99% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 2,431,718 shares of company stock worth $62,090,254. Insiders own 0.45% of the company’s stock.

Institutional Investors Weigh In On Vor Biopharma

A number of hedge funds have recently modified their holdings of the business. Goldman Sachs Group Inc. lifted its holdings in Vor Biopharma by 218.2% in the 1st quarter. Goldman Sachs Group Inc. now owns 84,945 shares of the company’s stock worth $61,000 after purchasing an additional 58,247 shares in the last quarter. XTX Topco Ltd bought a new position in Vor Biopharma during the 2nd quarter valued at about $66,000. OMERS ADMINISTRATION Corp purchased a new stake in Vor Biopharma in the first quarter worth about $100,000. Jane Street Group LLC purchased a new position in Vor Biopharma during the 1st quarter valued at about $140,000. Finally, Ariose Capital Management Ltd bought a new stake in shares of Vor Biopharma in the 3rd quarter valued at about $5,368,000. Institutional investors own 97.29% of the company’s stock.

Vor Biopharma Price Performance

Shares of Vor Biopharma stock traded down $8.97 during trading on Tuesday, hitting $9.83. The company’s stock had a trading volume of 7,295,412 shares, compared to its average volume of 423,422. The business’s fifty day moving average price is $31.32. Vor Biopharma has a 52 week low of $2.62 and a 52 week high of $65.80. The firm has a market capitalization of $67.34 million, a P/E ratio of -0.04 and a beta of 2.02.

Vor Biopharma (NASDAQ:VOR) last released its quarterly earnings data on Tuesday, August 12th. The company reported ($43.60) earnings per share (EPS) for the quarter, missing the consensus estimate of ($11.40) by ($32.20).

Vor Biopharma Company Profile

Vor Biopharma, Inc, a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company’s VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells.